Biotech Archives - Page 25 of 795

2 minute read

Novo Nordisk’s Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review

May 22, 1:21 PM

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will review Novo Nordisk's application for once-weekly insulin icodec on May 24. Concerns include an increased risk of hypoglycemia in type 1 diabetes patients.

NVO

3 minute read

Cannabis Rescheduling Signals Strong Returns, Tax Breaks Could Increase This Stock’s Market Cap By 170%

By Nicolas Jose Rodriguez

May 22, 12:50 PM

According to a recent report by Pablo Zuanic of Zuanic & Associates, MariMed (OTC: MRMD) a multi-state cannabis operator (MSO) is positioned for significant stock gains.

MRMD

2 minute read

Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks’ Cells

By Vandana Singh

May 22, 12:27 PM

The estate of Henrietta Lacks can proceed with a lawsuit against Ultragenyx Pharmaceutical over the use of HeLa cells taken without her consent in the 1950s. A Maryland federal court ruled against Ultragenyx's motion to dismiss, allowing the case to continue.

RARE

1 minute read

Australia Bans Replica Versions Of Popular Weight-Loss Drugs From Novo Nordisk, Eli Lilly On Safety Concerns

By Vandana Singh

May 22, 11:46 AM

Compounding weight loss drugs, which are similar to brand-name medications such as Ozempic and Mounjaro, will be banned in Australia.

LLY

1 minute read

Kymera Therapeutics To Present New Preclinical Data For KT-621, An Oral STAT6 Degrader At The ATS Annual Meeting; KT-621 Expected To Start Phase 1 In The Second Half Of 2024, With Phase 1 Data In The First Half Of 2025

By Benzinga Newsdesk

May 22, 11:27 AM

KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting Additional KT-621

KYMR

2 minute read

NeuroBo Pharmaceuticals Stock Slides Despite Animal Study Showing Wegvoy, Liver Fibrosis Success

By Vandana Singh

May 22, 10:55 AM

NeuroBo says DA-1241 data shows improved liver fibrosis and additive hepatoprotective effects when combined with semaglutide.

NRBO

1 minute read

Tivic Health, Feinstein Institutes Partner To Advance Its Patent-Pending, Non-Invasive Cervical Vagus Nerve Stimulation; Begins Optimization Of ncVNS For Use In Clinical Indications

By Benzinga Newsdesk

May 22, 9:10 AM

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today it has initiated the second phase of its clinical work to

TIVC

1 minute read

NanoVibronix Presents UroShield Clinical Study At The University Of Michigan

By Benzinga Newsdesk

May 22, 8:36 AM

NanoVibronix, Inc. (NASDAQ:NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced

NAOV

1 minute read

Indaptus Therapeutics First Patient Received Multiple Doses Of Decoy20, The Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy For Advanced Solid Tumors

By Benzinga Newsdesk

May 22, 8:16 AM

First-in-human trial confirms "Pulse-Prime" hypothesis targeting stimulation of innate and adaptive immune systemsInvestigational package of broad immune agonists derived from Gram-negative bacteria which induces dozens

INDP

1 minute read

VBI Vaccines To Present New Interim Phase 2b Data From VBI-1901 In Recurrent Glioblastoma Patients In Poster Presentation At 2024 ASCO Annual Meeting

By Benzinga Newsdesk

May 22, 8:04 AM

VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the

VBIV